Moderna — The Efficacy Of Following The Money

If you are expecting an erudite and pithy exposition of my considerable knowledge on COVID (I am a veteran of the ‘Vid) and my extensive wisdom as an Internet immunologist, public health official, medical raconteur, and epidemiologist — you will be disappointed. I am sorry.

Today, I speak only of one company – Moderna.

The Pandemic has been very good to Moderna — this is not a slur or a casting of aspersions of any form whatever. It is simply a reflection of Moderna’s stock price.

As you can seeĀ  being a Moderna common shareholder has been a damn good ride.

1-5-2020, $18.89/share

9-12-2021, $439.38/share

11-27-2021 afterhours, $336.07/share

If one goes back and studies Moderna’s stock price, one finds it has been a lackluster performer until the advent of the China Virus.

What exactly are you saying or implying, Big Red Car?

Absolutely nothing, dear reader. Just interesting to me, that’s all.

Have a great week.